Global Myasthenia Gravis Market to See Significant Growth to 2021, Informs Daedal Research in Its New Report Published at MarketPublishers.com

18 Aug 2017 • by Natalie Aster

LONDON – Myasthenia gravis is defined as a chronic neuromuscular disease caused by an error of nerve impulses to muscles, and resulting in weakness in the skeletal muscles helping in breathing and movement of the body parts. This disorder is recognised as a rare one: myasthenia gravis affects only 14-20 people out of every 100 thousand.

The major existing treatment option for myasthenia gravis comprise rapid short-term immune-modulating treatment, symptomatic treatment, surgery and chronic long-term immune-modulating treatment.

Over the past several years, the world’s market for myasthenia gravis has witnessed remarkable increase. This market is predicted to grow further, registering significant growth rates from 2017 till 2021, driven by a slew of encouraging factors such as surging geriatric population, approval of monoclonal antibodies, technological innovations and advancements, strategies like mergers and acquisitions, to name a few. However, the global market for myasthenia gravis is also facing a range of challenges including intensifying competition from off-label drugs, poor availability of FDA approved drugs, and high treatment cost.

On the basis of geography, the Americas are set to remain the leading regional myasthenia gravis market through 2021.

New publication “Global Myasthenia Gravis Market: Size, Trends & Forecasts (2017-2021) by Daedal Research provides a profound analysis of the myasthenia gravis marketplace on the global and regional scales. The report pays special attention to the market size, growth rates, values, shares and segmentation (based on therapy, cases, severity). Additionally, this insightful research publication offers a detailed review of the USA market for myasthenia gravis with vital details on the number of patients and types of the disease. The market dynamics (including key growth driving and limiting factors), major ongoing and emerging opportunities, and prevailing trends are observed here, too. Moreover, the report highlights the market growth prospects and gives detailed forecasts up to 2021.   

Profiles of the main companies such as Avadel Pharmaceuticals, Hoffmann-La Roche, Pfizer, and Argenx are available in the report. Each profile comprises relevant data on a company’s financial and business performance and major strategies.

A full list of insightful reports elaborated by Daedal Research is available at the publisher's page at MarketPublishers.com.

CONTACTS

The Market Publishers, Ltd.
Natalie Aster
Tel: +44 208 144 6009
Fax: +44 207 900 3970
ps@marketpublishers.com
MarketPublishers.com